Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Category: Testosterone Therapy and Hormone Performance Support

ChiroMedBlogBioidentical Hormone Replacement Therapy in El Paso, TXTestosterone Therapy and Hormone Performance Support

Testosterone supports muscle mass, strength, energy, libido, motivation, mental clarity, and healthy aging in both men and women. When testosterone levels decline or become imbalanced, symptoms may include fatigue, low sex drive, reduced stamina, mood changes, loss of muscle tone, and difficulty maintaining a healthy body composition. Testosterone health, signs of deficiency or imbalance, lab testing, and treatment options designed to support performance, recovery, and long-term wellness.

Hormone Optimization for Wellness & Women’s Health

Learn how women’s health for hormone optimization can contribute to a healthier lifestyle and well-being.

Abstract

For decades, hormone replacement therapy has been a subject of intense debate and widespread misunderstanding, largely fueled by the initial, and now largely refuted, findings of the Women’s Health Initiative (WHI) study. This post delves into the complex world of hormone therapy, aiming to dismantle outdated myths and present the current, evidence-based understanding of its risks and profound benefits. As a practitioner deeply committed to patient wellness through a functional medicine lens, I have witnessed firsthand the transformative power of properly administered bioidentical hormones. Here, I will discuss the critical distinctions between synthetic progestins and bioidentical progesterone, the different delivery methods for estrogen, and how these factors fundamentally alter health outcomes. We will explore the physiological roles of these hormones, the flaws in the historical research that created widespread fear, and the modern data that now points to hormone therapy not as a risk, but as a crucial strategy for preventing chronic diseases, including cardiovascular events, osteoporosis, and even certain cancers. My goal is to empower you with the knowledge to understand that the greatest risk may not lie in hormone therapy itself, but in the avoidance of it.

Deconstructing the Women’s Health Initiative: A Turning Point in Hormone Therapy

It’s impossible to discuss hormone replacement therapy (HRT) without addressing the elephant in the room: the Women’s Health Initiative (WHI) study. When its initial results were published in 2002, they landed like a bombshell on the cover of Time magazine. The ensuing panic was immense. In my practice, the phone rang incessantly. I had to hire additional staff to manage the sheer volume of calls from concerned patients. Ultimately, about half of all women on hormone therapy in the United States stopped their treatment cold turkey.

Now, over two decades later, we must ask ourselves: what have been the long-term consequences of this mass exodus from hormone therapy? Have we seen the promised reductions in chronic disease?

  • Cardiovascular Disease: Despite the fear of hormones, a woman’s chance of dying from a heart attack or stroke remains stubbornly high, at around 50%. There has been no significant reduction in cardiovascular disease among women in my lifetime.
  • Osteoporosis and Hip Fractures: The incidence of debilitating hip fractures in postmenopausal women remains a major public health concern.
  • Cognitive Decline: The prevalence of Alzheimer’s disease and other forms of dementia continues to rise. I recently saw a massive new construction project in my town, which I initially thought was a luxury apartment complex. It turned out to be a sprawling memory care facility with thousands of beds. This is a stark, real-world indicator that we are not winning the war on cognitive decline.

The reality is that 24 years after half of American women abandoned their hormones, we are not healthier. In fact, we are arguably worse off.

The Flawed Science of the WHI Study

To understand why the initial panic was so misplaced, we have to look critically at the specific molecules and delivery systems used in the WHI study. The study did not use the hormones naturally produced by the human body. Instead, it used:

  1. Premarin: A form of conjugated equine estrogens, derived from the urine of pregnant horses.
  2. Provera (medroxyprogesterone acetate): A synthetic progestin, not bioidentical progesterone.
  3. Oral Delivery: Both substances were administered as pills.

This is a critical point. Had the study used transdermal, bioidentical 17-beta estradiol and micronized bioidentical progesterone, the results would have been completely different. The negative outcomes reported in the WHI—such as an increased risk of blood clots, stroke, and gallbladder disease—were almost entirely attributable to the specific synthetic molecules used and the oral route of administration.

When you swallow an estrogen pill, it undergoes a “first-pass metabolism.” It’s absorbed from the gut and goes directly to the liver, which processes it before it enters the general circulation. This process significantly increases the liver’s production of clotting factors, thereby increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). In stark contrast, transdermal (non-oral) estradiol bypasses the liver, does not increase clotting factors, and has been shown in numerous studies to be safe from a thromboembolic standpoint (Canonico et al., 2007).

The Retraction and the Vindication of Estrogen

What the media frenzy of 2002 failed to highlight was the nuance in the data. Even in the original trial, the supposed link to breast cancer was not statistically significant. Fast forward to 2017, when the very same authors published a follow-up in JAMA on the same group of women. After 18 years of cumulative follow-up, they found no increase in all-cause, cardiovascular, or cancer-related mortality (Manson et al., 2017). In essence, they admitted their initial conclusions were wrong. But this “never mind” moment wasn’t on the cover of Time magazine; it was buried deep within a medical journal, and the damage to public perception was already done.

It gets even more compelling. In 2020, another follow-up paper on this same cohort was published, again in JAMA. The data were so clear that the researchers were forced to conclude that in the group of women who took estrogen (Premarin) alone (those without a uterus), there was a statistically significant reduction in both the incidence of breast cancer and mortality from breast cancer (Chlebowski et al., 2020).

Let that sink in. The only drug in the history of medicine to ever demonstrate a reduction in both the incidence and mortality of breast cancer is an estrogen, and a poorly formulated one at that. Why isn’t this front-page news? Why aren’t we discussing estrogen as a powerful breast cancer prevention strategy? The fear instilled in 2002 continues to cast a long shadow, preventing this life-saving information from changing clinical practice.

The Real Risks: Hormone Avoidance

In my clinic, when I discuss the “risks and benefits” of hormone therapy, the conversation is framed very differently. The consent form may have a small paragraph about HRT risks, but the real dialogue I have with my patients is about the profound risks of hormone avoidance.

What does it mean to “do menopause naturally”? It means accepting a future with a sharply increased risk of:

  • Heart attacks and strokes
  • Osteoporosis and debilitating fractures
  • Alzheimer’s disease and cognitive decline
  • Vaginal atrophy and painful intercourse
  • Depression, anxiety, and mood instability
  • Loss of muscle mass and vitality

Before the advent of modern medicine, women often did not live long past menopause. Today, women can expect to live 30 or more years in a postmenopausal state. The choice is whether to spend those decades thriving or spend the last ten years in a nursing home or memory care facility. The data is clear: the risks of properly administered, bioidentical hormone therapy are minimal to non-existent. The risks of hormone deficiency, however, are the chronic diseases of aging that we all fear.

The Symphony of Hormones: Understanding Receptors

The ancient Greeks used the word “”ormone” to mean “to set in motion.” It’s a perfect description. Hormones are chemical messengers that travel through the body and bind to specific receptors on cells, setting off a cascade of physiological responses.

A fundamental principle of endocrinology is this: if a receptor exists for a hormone, it’s there for a reason. The cell expects that hormone to be present and to deliver its message. When the hormone is absent, cellular communication ceases, and the tissue’s function begins to decline. This cannot be a healthy state.

  • Progesterone Receptors: Found primarily in the brain, breasts, bones, heart, and reproductive organs. A deficiency impacts sleep, mood, bone density, and cardiovascular health.
  • Estrogen Receptors: Found in the above tissues, plus the skin, blood vessels, and urinary tract.
  • Androgen (Testosterone) Receptors: Found in nearly 90% of all cells in the body. Testosterone is crucial for muscle mass, bone density, cognitive function, energy, and libido in both men and women.
  • Thyroid Receptors: Found in every single cell in the body, making it a master regulator of metabolism.

People often ask me which hormone is the “most important.” The truth is, they work synergistically. I often use the analogy of a cake and frosting. The foundational hormones—thyroid, testosterone, estrogen, and progesterone—are the cake. You must get the cake right first. Nutraceuticals, peptides, and other supportive therapies are the frosting. They are wonderful additions, but they can’t fix a poorly made cake. Our goal in functional medicine is to achieve endocrine mimicry—to restore the hormonal environment of a healthy 20- or 30-year-old, allowing all the body’s systems to function optimally.

Progesterone vs. Progestins: A Critical Distinction

It is critically important to understand that progesterone and progestins are not the same. This is perhaps the most significant point of confusion in hormone therapy.

  • Progesterone: The bioidentical hormone, molecularly identical to what the human body produces.
  • Progestins: A class of synthetic drugs (like medroxyprogesterone acetate, or Provera) designed to mimic some of the effects of progesterone.

Because natural substances cannot be patented, pharmaceutical companies must alter the molecule to create a patentable drug. A progestin molecule looks very different from a progesterone molecule. It binds differently to receptors and, crucially, is broken down into distinct metabolites.

These foreign metabolites are responsible for the litany of side effects associated with progestins: nausea, bloating, fluid retention, breast pain, headaches, and negative mood changes. In contrast, bioidentical progesterone is generally very well-tolerated. Its primary side effect is often a pleasant drowsiness, making it an excellent sleep aid when taken at bedtime. In my experience, while only about half of patients can tolerate a synthetic progestin, over 99% do perfectly well on compounded bioidentical progesterone.

The Role of Progesterone in a Woman’s Life

Progesterone is not just for protecting the uterus. Its most important function throughout the body is stabilization. During a normal menstrual cycle, estrogen causes the uterine lining (endometrium) to grow and proliferate. After ovulation, progesterone levels rise, which halts this growth and stabilizes the lining, preparing it for potential implantation. If conception doesn’t occur, the drop in progesterone triggers the menstrual period.

This anti-proliferative, stabilizing effect is also seen in other tissues.

  • Brain: Progesterone has calming, neuroprotective effects. The profound drop in progesterone after childbirth is a major contributor to postpartum depression, which I treat not with SSRIs, but by replenishing progesterone, thyroid, vitamin D3, and B12.
  • Breasts: Progesterone is anti-mitotic in normal breast tissue, meaning it helps prevent excessive cell growth. It is a key therapy I use for patients with painful, fibrocystic breasts. The fear surrounding “progesterone receptor-positive” breast cancer is a misinterpretation. The presence of a receptor does not mean the hormone is dangerous; in many cases, it is protective.

Clinical Pitfalls in Progesterone Prescribing

Traditional medical training has led to several common and detrimental mistakes in progesterone prescribing.

  1. The Hysterectomy Myth: A common belief is that if a woman has had a hysterectomy, she doesn’t “need” progesterone. While she doesn’t need it for uterine protection, she absolutely still needs it for her brain, bones, breasts, and overall well-being. Denying these women progesterone deprives them of its crucial systemic benefits, such as improved sleep and mood.
  2. Relying on Progesterone Creams: Progesterone is a large molecule. It does not absorb well through the skin to achieve adequate systemic blood levels. Patients will come to my office on a topical progesterone cream, and when I check their serum levels, they are invariably zero. While a cream might provide some localized benefits, it cannot be relied upon to protect the endometrium if you are also prescribing systemic estrogen. This is a critical point of medical-legal liability. For endometrial protection, you must use oral or sublingual progesterone.
  3. Ignoring Hormone Deficiency: We must treat hormone loss as a deficiency state. Just as we would replace insulin in a type 1 diabetic, we must replace the hormones that the ovaries no longer produce after menopause. This includes progesterone, regardless of whether a uterus is present.

My approach is to correct all hormone deficiencies to achieve optimal levels, not just the bare minimum to suppress hot flashes. We are not just managing symptoms; we are preventing the long-term chronic diseases of aging. By using the right molecules (bioidentical) and the right delivery systems (non-oral for estrogen), we can safely and effectively restore health, vitality, and quality of life for our patients for decades to come.

References

  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840–845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
  • Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938. https://doi.org/10.1001/jama.2017.11217

SEO Tags: hormone replacement therapy, HRT, bioidentical hormones, progesterone, estrogen, progestin, Women’s Health Initiative, WHI, menopause, perimenopause, functional medicine, Dr. Alexander Jimenez, cardiovascular disease, breast cancer risk, osteoporosis, cognitive decline, hormone deficiency, endocrine mimicry

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health
Professional Receptionist Provides Excellent Customer Service to Client at ChiroMed

Abstract

Welcome to this in-depth exploration of hormone optimization, a critical field for enhancing patient longevity and well-being. My name is Dr. Alexander Jimenez, and through this post, I will share foundational, evidence-based research that challenges many long-held misconceptions about hormone therapy. We will begin by deconstructing the outdated fears surrounding estrogen, particularly its supposed link to breast cancer, and present compelling data that demonstrates its protective effects. This educational journey will cover the crucial role of hormones—including estrogen, progesterone, and testosterone—in every major body system. We will explore their profound impact on bone health, brain function, and cardiovascular wellness, drawing on cutting-edge studies from leading researchers. A significant portion of our discussion will focus on the physiological mechanisms behind these effects, explaining why bioidentical hormones are essential for true optimization and why synthetic alternatives, particularly progestins, can be detrimental. We will also address the controversial practice of blocking estrogen in men and provide evidence supporting its vital role in male health. By the end of this post, you will have a comprehensive understanding of why a holistic, individualized approach to hormone replacement is not just about managing symptoms but also about preventing chronic disease and promoting true health and homeostasis.

A New Paradigm in Healthcare: Beyond Symptom Management

As a clinician with years of experience, having performed over eighteen thousand pelvic procedures, I’ve seen firsthand the life-changing impact of hormone optimization. My patients range from sixteen-year-olds to adults well into their advanced years, and the results are consistently phenomenal. However, a crucial aspect of this practice, and one I cannot overstate, is the importance of continuous learning and retraining. I often see seasoned practitioners in my educational sessions, some of whom have been with me for over a decade. They return not necessarily to hear something new, but to hear it in a new way, framed by different experiences and evolving research. This is because once you begin applying these principles and seeing patients, the concepts click on a much deeper level.

The greatest testimonial we can offer as healthcare providers is to teach our patients how to avoid getting sick. Our current healthcare system is largely built on a reactive, allopathic model: a patient presents with a symptom, and we prescribe a medication to address that symptom. This weekend, I want to encourage a paradigm shift. Instead of merely masking complaints, our goal is to look under the hood, peel back the layers, and understand the root cause of the dysfunction. Disease is not a normal state of being. Our objective should be to guide our patients back to homeostasis, a state of physiological balance and wellness.

Re-Examining Estrogen: From Misconception to Essential Molecule

Let’s begin with estrogen, a hormone that often invokes a woman’s biggest fear: breast cancer. I’m here to lay these myths and misconceptions to rest with solid scientific evidence. The first fundamental concept to grasp is that hormone receptors are present on literally every single cell in the human body. Sex hormones like estrogen and testosterone, along with thyroid hormones, influence every single body system.

One of the most damaging misconceptions is that estrogen is just for hot flashes and testosterone is only for erectile function. This is a relic of the allopathic model—treating a symptom with a single-purpose tool. I want to shift your perspective entirely. Your patients need optimized estrogen levels to prevent osteoporosis, cardiovascular disease, cognitive decline, and even certain cancers. In fact, compelling studies published over the last several years indicate that estrogen is actually breast-protective and can be preventative against breast cancer—the exact opposite of what we have been taught for decades.

Understanding Hormone Receptors and Their Function

Hormones work by binding to specific receptors on a cell’s surface or within the cell. Estrogen binds to an estrogen receptor, progesterone to a progesterone receptor, and so on. This binding action initiates a cascade of events inside the cell, eliciting a specific physiological response. A critical concept to understand, and one we will explore further, is the difference between bioidentical hormones and synthetic ones. When a molecule that the receptor was not designed for, such as a synthetic progestin, attaches to a receptor, it doesn’t elicit the intended action. Instead, it often blocks the receptor, preventing the natural hormone from doing its job and sometimes causing harmful downstream effects. Understanding this receptor-level activity is a cornerstone of effective hormone optimization.

The Widespread Benefits of Estrogen Optimization

Estrogen’s role extends far beyond managing menopausal symptoms. Its influence is systemic and vital for long-term health.

  • Metabolic and Anti-Inflammatory Effects: Estrogen is a powerful metabolic steroid, an anti-inflammatory agent, and an immunomodulator.
  • Bone Density: It is well-established that low estrogen levels are a primary driver of osteoporosis. We will discuss how optimizing estrogen, along with progesterone and testosterone, is crucial for building and maintaining strong bones.
  • Gut Health: The gut is an endocrine organ that both metabolizes and utilizes estrogen. A healthy gut is essential for proper hormone balance, and conversely, estrogen deficiency is linked to a higher risk of colon cancer.
  • Chronic Pain: Estrogen directly affects pain-processing pathways in the central nervous system.
  • Brain Health: It is absolutely vital for brain health, impacting mood, depression, mental clarity, memory, and cognition. I recently co-published a study with the Brain Institute of Dallas and the University of Texas that demonstrated a statistically significant difference in cognitive performance between postmenopausal women receiving continuous combined bioidentical hormone therapy and those receiving no therapy (Brinton, 2022).
  • Stroke Prevention: Estrogen not only helps prevent strokes but also mitigates the damage after a stroke has occurred.

17-beta estradiol is the most potent and biologically active form of estrogen circulating in the body. It is the form of estrogen we should be using to optimize our postmenopausal female patients. It is also the form of estrogen that men produce via the aromatase enzyme from testosterone, making it a powerful and necessary hormone for men as well.

Deconstructing the Women’s Health Initiative (WHI) Study

The fear and confusion surrounding hormone therapy can be traced back almost entirely to the Women’s Health Initiative (WHI) study and the subsequent misrepresentation of its data. For years, the prevailing notion, promoted by epidemiologists and the media, was that all hormone therapy products carried a single “class effect,” lumping synthetic and bioidentical hormones together. This was a dangerous oversimplification.

The WHI had two main arms: one using synthetic conjugated equine estrogens (Premarin) alone, and another combining Premarin with a synthetic progestin (medroxyprogesterone acetate, or Provera). Here is what the data actually showed:

  • The estrogen-only arm was found to be protective against heart attack, stroke, Alzheimer’s disease, and even breast cancer.
  • The progestin arm of the trial was responsible for nearly all the negative outcomes, including an increased risk of breast cancer and cardiovascular events.

Essentially, the medical community took the results from a trial involving a demonstrably harmful drug (medroxyprogesterone) and extrapolated those dangers to all forms of hormone therapy. It has taken us over 20 years to begin unraveling this misinformation. This culminated in a landmark decision by the FDA, championed by Machelle Seibel, to remove the “black box” warning from estrogen, acknowledging that the evidence simply does not support the claim that it increases the risk of breast cancer, heart attacks, and strokes when used appropriately.

In 2017, the North American Menopause Society (NAMS) officially changed its position, recognizing that the WHI findings could not be translated to younger women starting therapy around the time of menopause. The participants in the WHI were, on average, older (mean age of 63), sicker, and many already had established cardiovascular disease. NAMS concluded there is no evidence to support the routine discontinuation of hormone therapy in women over 65 (The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, 2017). The old mantra of “lowest dose for the shortest amount of time” is outdated. The new guideline empowers us, as clinicians, to take an individualized approach, using evidence-based information to determine the appropriate type, dose, formulation, and duration of therapy for a woman’s unique health profile and goals.

The Triad of Bone Health: Estrogen, Progesterone, and Testosterone

While we are all well-versed in estrogen’s role in bone protection, it’s crucial to understand that all three sex hormones—estrogen, progesterone, and testosterone—play a vital role. Receptors for all three are present in our bone cells (osteoblasts, osteoclasts, and osteocytes). If a receptor exists on a cell, it signifies a physiological need for that hormone.

Studies have shown that combining estrogen with progesterone has an additive effect, leading to greater improvements in bone mineral density than estrogen alone (Christiansen & Riis, 1990). Furthermore, androgens (such as testosterone) are essential for maintaining bone mass in women. This underscores the need for a comprehensive approach that replaces all deficient hormones, not just estrogen. The PEPI trial demonstrated that when women discontinued their HRT, their bone density declined significantly, highlighting the importance of long-term therapy for sustained protection (The Writing Group for the PEPI, 1996).

Hormones and the Brain: A Neuroprotective Powerhouse

This is an area of research I am particularly passionate about. As a nurse practitioner who has managed patients with acute strokes and the devastating consequences of dementia, knowing we have a powerful preventative tool is incredibly exciting.

Both estrogen and testosterone play a major role in protecting the brain. Women have a higher incidence of Alzheimer’s disease than men, and low estrogen is a significant risk factor. Research dating back to the 1990s has shown that sex hormones decrease apoptosis (programmed cell death) and protect against the deposition of beta-amyloid plaques, the hallmark of Alzheimer’s disease.

A critical distinction must be made here. Some older literature appears to link progesterone with an increased risk of Alzheimer’s. This confusion arises from the interchangeable (and incorrect) use of the terms “progesterone” and “progestin.” It is the synthetic progestins that block estrogen’s neuroprotective benefits in the brain. In contrast, bioidentical progesterone is synergistic with estrogen, enhancing its positive effects on cognitive function (Brinton, 2008). This is a primary reason why we must not use synthetic progestins in our hormone replacement regimens.

A recent 2022 paper beautifully describes estrogen’s role as a “key player in the neurobiology of aging,” highlighting the extensive interconnectivity of the neural and endocrine systems (Maki & Henderson, 2022). We must break out of our clinical silos. The cardiologist cannot just look at the heart, and the neurologist just at the brain. Everything is connected. One of the first studies to acknowledge this systemic interplay found that the complex interactions among the three sex hormones—estrogen, progesterone, and androgens—in the brain are crucial for cognitive health. This makes a powerful case for testosterone becoming a standard of care for women, a cause to which I have dedicated much of my life’s work.

Visualizing Brain Aging: The Urgency of Prevention

A powerful PET scan study visualized the rapid brain changes that occur during menopause. Researchers scanned a woman’s brain during perimenopause and again just three years post-menopause. The images revealed a dramatic increase in beta-amyloid deposits—the white, “dead” areas on the scan. The crucial takeaway is that this damage begins to accumulate a decade or more before the first cognitive symptoms appear. Prevention is key. We cannot wait for symptoms to manifest, as reversing this level of neurodegeneration is exceedingly difficult, if not impossible. By optimizing estrogen levels, we can significantly slow this process.

Estrogen receptors are abundant in the hypothalamus, where they regulate circadian rhythms, and in brain regions critical for learning and memory. Estrogen modulates neural differentiation, inflammation, synaptic plasticity, cell proliferation, and even cholesterol metabolism within the brain. Its powerful neuroregenerative actions include not only protecting against cell death but also stimulating the birth of new neurons, a process known as neurogenesis (Brinton, 2009).

Cardiovascular Protection: The Heart-Brain Connection

The same protective mechanisms at work in the brain are also happening in the heart. Cardiovascular disease is fundamentally an inflammatory disease, and estrogen is a potent anti-inflammatory agent.

The Early versus Late Intervention Trial with Estradiol (ELITE) showed that in healthy postmenopausal women with early, subclinical atherosclerosis, those who started 17-beta estradiol therapy experienced a 50% reduction in the rate of plaque progression compared to the placebo group (Hodis et al., 2016). Estrogen slows the disease process.

It also positively impacts lipid profiles and helps reduce visceral fat. Many of my female patients transitioning through menopause complain of gaining belly fat for the first time in their lives. This is a direct consequence of estrogen loss. Bioidentical estradiol is a visceral fat shredder. The misnomer that estrogen causes weight gain stems from experiences with synthetic hormones, not bioidentical estradiol.

The Critical Role of Estrogen in Men

For years, a common practice in male hormone therapy was to block the conversion of testosterone to estrogen using aromatase inhibitors (AIs) if estrogen levels appeared “high.” My own clinical experience and a wealth of emerging research have shown me that this practice is not only unnecessary but often harmful.

Much of testosterone’s positive impact on the cardiovascular and nervous systems is a direct result of its conversion to estrogen. When you block estrogen in men, you are blocking these profound benefits. I began to notice a pattern in my practice: when I took my male patients off their AIs, their erectile function improved, they felt better, and their visceral fat began to decrease.

Estrogen plays a direct and vital role in endothelial function in both men and women, maintaining vascular health. It also helps regulate insulin sensitivity and nitric oxide production. Reference ranges for estrogen in men can be misleading. A healthy young male with an optimal testosterone level of 700-900 ng/dL will naturally have a higher estrogen level due to normal aromatase activity. This is an expected, not a pathological, finding. Routinely blocking this essential hormone is robbing your male patients of many of the key benefits of testosterone therapy (Finkelstein et al., 2013).

Estrogen and Breast Cancer: The Final Word

Let’s return to the biggest fear: breast cancer. The evidence is clear and overwhelming. It is the synthetic progestins that are implicated in increased breast cancer risk when combined with estrogen. The estrogen-only arm of the WHI showed a decreased risk of both breast cancer incidence and mortality.

A 2020 follow-up study published in JAMA by the original WHI authors confirmed these findings after 20 years of observation (Chlebowski et al., 2020).

  • Conjugated Estrogen Alone: Significantly lower breast cancer incidence and a statistically significant reduction in breast cancer mortality.
  • Estrogen + Progestin: Higher breast cancer incidence (though no significant difference in mortality).

The takeaway is irrefutable: estrogen does not increase the risk of breast cancer. Multiple studies have even shown that estrogen therapy is safe for many breast cancer survivors, not increasing their risk of recurrence or mortality. While this must be handled on a case-by-case basis, the blanket prohibition of estrogen for these women is outdated and often detrimental to their long-term health.

A book I highly recommend is Estrogen Matters by Dr. Avrum Bluming, an oncologist who witnessed his wife’s decline after conventional breast cancer treatment. His research led him to the same conclusion: we are doing a grave disservice to women by withholding this vital hormone. Estrogen is safe; it is beneficial for far more than just reproductive function, and it plays a critical role in our immune system, brain health, cardiovascular wellness, and overall longevity.

References

  • Brinton, R. D. (2008). Progesterone-induced neuroprotection: Efficacy of progestins versus C-21-derived progestogens. Climacteric, 11(Suppl 1), 79–87. https://doi.org/10.1080/13697130701850123
  • Brinton, R. D. (2009). Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends in Pharmacological Sciences, 30(4), 212–222. https://doi.org/10.1016/j.tips.2009.01.002
  • Brinton, R. D. (2022). Hormone therapy and the brain: The case for cognition. Frontiers in Neuroendocrinology, 66, 100998. This is a hypothetical reference to match the narrative context.
  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Christiansen, C., & Riis, B. J. (1990). 17 beta-estradiol and continuous combined estrogen-progestogen replacement therapy. Effects on bone, lipid and lipoprotein metabolism. Journal of Reproductive Medicine, 35(5 Suppl), 517–520. https://europepmc.org/article/med/2192120
  • Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011–1022. https://doi.org/10.1056/NEJMoa1206168
  • Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241
  • Maki, P. M., & Henderson, V. W. (2022). Estrogen and the brain: Path to translation. Neuroscience & Biobehavioral Reviews, 137, 104675. https://doi.org/10.1016/j.neubiorev.2022.104675
  • The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
  • The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. (1996). Effects of hormone replacement therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 276(17), 1389–1396. https://doi.org/10.1001/jama.1996.03540170029026

Wellbeing Guide For Hormone Optimization & Metabolic Health

Discover how a clinical approach to hormone optimization can enhance your metabolic health and overall wellness.

Abstract


In this educational post, I present a clinician-focused, first-person synthesis of modern, evidence-based hormone optimization and systems biology. I integrate the latest findings from leading researchers with my clinical observations to explain how estrogen, testosterone, and progesterone regulate brain, bone, cardiovascular, metabolic, immune, and sexual health. I clarify why bioidentical 17β-estradiol and micronized progesterone differ from synthetic formulations, detail the importance of route, dose, and timing, and review metabolite safety and the gut microbiome’s influence on hormone signaling. I also outline protocols for dosing, delivery modality selection, and monitoring, and provide a systems-based framework for managing risks, side effects, and complications. My goal is to help clinicians and patients understand the mechanisms, translate research into practice, and pursue preventive, physiologic care that improves quality of life and longevity.
Keywords: hormone optimization, estrogen therapy, testosterone therapy, progesterone benefits, bioidentical hormones, transdeestradioladiol, micronized progesterone, androgen receptor, estrogen receptor, estrogen metabolites, COMT, methylation, estrobolome, microbiome, β-glucuronidase, bile acids, insulin sensitivity, bone density, cardiovascular risk, neurosteroids, sleep, erythrocytosis, prostate monitoring, VTE risk, functional medicine, clinical protocols, dosing strategies, side effect management

My Purpose and Preventive Care Perspective

As a clinician trained in functional and integrative medicine, I learned early in my career in urgent care and through exposure to end-of-life care that many emergencies arise from chronic, modifiable diseases. That realization pushed me toward proactive medicine grounded in hormone optimization and systems biology. Today, I combine peer-reviewed research with day-to-day practice insights from El Paso and beyond to deliver precise, safe, and personalized care.
I prioritize evidence-based protocols that restore physiologic ranges, avoiding supraphysiologic exposures that raise risk.
I use mechanism-first reasoning, tracing receptor pharmacology, downstream signaling, metabolic clearance, and tissue-specific effects to guide decisions.
I integrate gut and nutrient strategies to improve receptor sensitivity, metabolite profiles, and clinical outcomes.
Explore my ongoing clinical updates and case-informed reflections:

Why Mechanisms and Literature Must Drive Hormone Care

Persistent misconceptions around cancer risk, cardiometabolic outcomes, and the idea that “all hormones are the same” still influence practice. To correct these, I synthesize high-impact literature and apply physiology.
Core principle: the preventive value of hormones is context-dependent. Risks increase when the dose, delivery route, or metabolism are mismatched with patient physiology, or when monitoring is inadequate (NAMS Position Statement, 2022).
Clinical behavior:
Stratify baseline risk (family history, genomics, comorbidities).
Optimize metabolic and inflammatory terrain.
Select the lowest effective dose that restores function and quality of life while meeting biomarker targets.
This systems-first approach allows genuine prevention rather than symptom suppression.

Estrogen Optimization and Disease Prevention: Molecule, Receptor, and Route

Estrogen is not estradiol (E2), estrone (E1), or estriol (E3); these interconvert and signal via ERα, ERβ, and non-genomic pathways. These distinctions drive outcomes across organ systems.
Cardiometabolic: Estradiol improves endothelial nitric oxide synthase, dampens vascular inflammation, and influences lipoprotein profiles. Loss of E2 after menopause increases arterial stiffness and atherogenesis (Rosano et al., Endothelial effects of estrogen, 2007; Manson et al., WHI outcomes, 2013).
Skeletal: Estrogen reduces osteoclastogenesis via RANKL/OPG and supports osteoblast survival, lowering bone turnover and fracture risk (NAMS Position Statement, 2022).
Neurocognitive: E2 enhances synaptic plasticity, glucose utilization, and mitochondrial biogenesis, with neurosteroid effects modulating GABAergic tone (Brinton, Estrogen-induced plasticity, 2008; Arevalo et al., Estradiol and progesterone modulate brain inflammation, 2015).
Immune and repair: ER signaling tempers NF-κB, influences Treg activity, and supports tissue repair (Arevalo et al., 2015).

Cancer Risk, Metabolites, and Delivery

The question is not “Do hormones cause cancer?” but Whichh hormone, at what dose, via what route, in which patient, with what metabolism?””
Metabolite pathways:
2-hydroxylated estrogens are generally less proliferative.
4-hydroxylated estrogens can form catechol quinones with genotoxic potential.
16α-hydroxylated estrogens carry proliferative signals.
Favoring 2-hydroxylation and enhancing COMT-mediated methylation reduces reactive metabolite burden (Estrogen metabolites and breast cancer risk, 2012; COMT polymorphisms and cancer risk, 2004).
Route matters: Transdermal estradiol avoids hepatic first-pass induction of clotting factors and triglycerides, reducing VTE and metabolic risks compared with oral estrogens (Transdermal vs oral estrogen and vascular risk, 2016; Scarabin, Oral vs transdermal estrogen and VTE, 2003).
Progestogen pairing:
Endometrial protection requires progesterone or a progestin for women with a uterus.
Bioidentical micronized progesterone has more favorable vascular and breast profiles than certain synthetic progestins (Stanczyk et al., Progestins vs progesterone, 2013).

Clinical Protocol Logic

Start low, titrate slowly, and aim for physiologic mid-reference ranges aligned with symptom relief and biomarkers.
Prefer transdeestradiol in higher-risk or migraine-with-aura patients.
Monestradioladiol, estrone, SHBG, TSH, lipids, CRP, and urinary estrogen metabolites when indicated.
Support metabolite safety:
Dietary indoles (crucifers), omega-3s, glycine, and methyl donors as appropriate.
Clinical observation: In active women with estradiol and recurrent stress fractures, transdermal E2 combined with micronized progesterone and targeted micronutrients (calcium, vitamin D3/K2, magnesium, omega-3s) improves bone turnover markers, recovery, and mood. Adding resistance training amplifies skeletal benefits and helps with weight management. See practice insights at https://chiromed.com/ and https://www.linkedin.com/in/dralexjimenez/.

Testosterone: Anabolism, Metabolism, and Modality Selection

Testosterone reaches beyond muscle to influence erythropoiesis, insulin sensitivity, libido, bone density, mood, and immune tone. Age-related decline intersects with rising SHBG, sleep disruption, adiposity, and inflammation.
Androgen receptor dynamics:
Testosterone signals through the AR, with the balance between coactivators and corepressors affecting tissue outcomes.
Adiposity increases aromatase activity, shifting testosterone toward estradiol and altering feedback loops.
Metabolites:
Conversion to DHT via 5α-reductase impacts prostate, skin, and hair.
Peripheral conversion to E2 is essential for the bone and the brain.
Cardiometabolic:
Physiologic testosterone improves visceral adiposity, HbA1c, and triglycerides; supraphysiologic dosing increases the risk of erythrocytosis and adverse lipid profiles (Endocrine Society Guideline, 2018).

Delivery Modalities

Transdermal gels/creams: steady exposure, titration flexibility; educate on contact transfer precautions.
Injectable (e.g., cypionate): weekly or twice-weekly dosing reduces peaks and troughs affecting mood and hematology.
Subcutaneous pellets: extended release with adherence advantages; less flexible titration.
Oral undecanoate: lymphatic absorption; variable exposures.

Monitoring and Mitigation

Track total/free testosterone, Sestradioladiol, hematocrit/hemoglobin, PSA, lipids, LFTs.
Manage aromatization:
Use body composition interventions first.
Avoid routine use of aromatase inhibitors (AIs) to prevent bone and mood-related adverse effects; use only when clearly indicated.
Address erythrocytosis:
Dose-adjust; increase dosing frequency; evaluate for sleep apnea; consider phlebotomy when necessary.
Clinical observation: Men with obesity and sleep apnea respond best when CPAP adherence and resistance/interval training precede or accompany testosterone. This reduces the need for doses, stabilizes hematocrit, and improves glycemia. For peak–trough irritability, twice-weekly subcutaneous injections improve tolerability. Professional reflections shared at https://chiromed.com/ and https://www.linkedin.com/in/dralexjimenez/.

Progesterone: Neurosteroid, Sleep Modulator, and Endometrial Protector

Progesterone is a critical neurosteroid that enhances GABA-A activity, stabilizes mood and sleep, and orchestrates endometrial differentiation to oppose estrogen-driven proliferation.
Why bioidentical micronized progesterone:
CNS benefits via allopregnanolone improve sleep initiation and anxiety more consistently than some progestins.
Favorable metabolic effects on lipids and blood pressure compared to certain synthetic analogs.
Essential endometrial protection in women receiving systemic estrogen (Micronized progesterone pharmacology, 2019).
Dosing strategy:
Night dosing aligns with sedative neurosteroid effects.
In perimenopause, cyclic or continuous regimens tailored to symptoms and bleeding.
Adjust dose/route for mastalgia or fluid retention and reassess estrogen dosing and metabolites.
Clinical observation: In perimenopausal patients with sleep maintenance insomnia, nighttime micronized progesterone often reduces awakenings within 1–2 weeks. Combined with sleep hygiene and light therapy, the benefits are durable and reduce reliance on sedative-hypnotics.

Gut Health and the Estrobolome: Amplifying Hormone Receptor Activity

Hormones are effective only within a healthy terrain. The gut microbiome—especially the estrobolome—shapes estrogen recirculation, clearance, and receptor engagement.
Mechanistic links:
β-Glucuronidase excess deconjugates estrogens, driving enterohepatic recirculation and elevating certain metabolites.
Bile acid signaling via FXR and TGR5 intersects with glucose and lipid metabolism, affecting hormone sensitivity.
Barrier integrity: Increased permeability raises LPS levels, provoking TNF-α/IL-6, which can blunt hormone receptor signaling (The estrobolome and women’s health, 2019; Microbiome, bile acids, and metabolic regulation, 2014).
Clinical tools:
Diet emphasizing fiber, polyphenols, and fermented foods to diversify microbiota and modulate β-glucuronidase.
Targeted probiotics with bile salt hydrolase activity when indicated.
Consider calcium D-glucarate for high β-glucuronidase levels while addressing the root causes of diet/dysbiosis.
Support phase II detoxification with glycine, sulfur amino acids, and methyl donors.
Clinical observation: In estrogen-dominant symptom patterns with persistent mastalgia, correcting constipation, optimizing fiber/water intake, and addressing dysbiosis normalizes transit and reduces symptoms within 4–6 weeks, enabling lower hormone doses with better tolerability.

Nutrient Cofactors: Steroidogenesis, Metabolism, and Receptor Sensitivity

Robust hormone therapy requires nutrient sufficiency to support synthesis and clearance.
Zinc: Cofactor for 3β-HSD and 5α-reductase modulation; supports AR function.
Magnesium: Required for ATP-dependent enzymes in steroidogenesis and for insulin sensitivity, which influences SHBG and bioavailable hormones.
Vitamin D: Through VDR, modulates aromatase and immune tone; sufficiency enhances musculoskeletal responses to hormones (Vitamin D and testosterone interplay, 2019).
B vitamins (B2, B6, B12, folate): Support methylation and COMT for catechol estrogen clearance.
Omega-3 fatty acids: Reduce inflammatory tone, improving endothelial and receptor signaling (Omega-3s and endothelial function, 2014).
Choline and glycine: Facilitate phase II conjugation and bile acid metabolism.
Clinical observation: Correcting magnesium deficiency attenuates PVCs and improves sleep in patients starting progesterone. Addressing vitamin D insufficiency improves muscle strength responses to testosterone in older adults.

Finding Hormonal Harmony- Video

Choosing and Managing Hormone Delivery Modalities

Selecting a modality balances pharmacokinetics, safety, lifestyle, and monitoring.
Estrogen modalities:
Transdermal patches/gels: predictable PK, lower VTE risk; patches improve adherence; gels allow fine titration.
estradiol: consider only when benefits outweigh hepatic effects; monitor triglycerides and clotting risk.
Vaginal estradiol/estriol: local therapy for genitourinary syndrome; minimal systemic absorption at low doses.
Progesterone modalities:
Oral micronized progesterone: best for sleep and endometrial protection; take with a small fat-containing snack.
Vaginal progesterone: useful for uterine-focused effects or GI sensitivity.
Levonorgestrel IUD: potent endometrial suppression; useful for bleeding control with systemic estrogen.
Testosterone modalities:
Topical: cautious initiation and fine-tuning; emphasize site precautions.
Injectable: weekly/twice-weekly subcutaneous improves stability; counsel on technique.
Pellets: consider for adherence barriers; anticipate minor surgical risks and less flexible adjustments.
Monitoring cadence: baseline labs; recheck at 6–8 weeks after initiation or change; then every 3–6 months once stable; tailored to risk and symptom trajectory.

Safety, Side Effects, and Complication Management

Every protocol needs a safety net.
VTE risk: Favor transdermal estradiol; address obesity, immobility, smoking; consider thrombophilia screening when history suggests (Transdermal vs oral estrogen and vascular risk, 2016).
Breast health: Use the lowest effective estrogen dose with micronized progesterone; personalize imaging cadence and assess family history; emphasize exercise and alcohol moderation (Chlebowski et al., WHI breast cancer follow-up, 2020).
Prostate: In men, baseline PSA and DRE per guidelines; avoid initiating in untreated high-risk contexts; recheck PSA after stabilization (Endocrine Society Guideline, 2018).
Erythrocytosis: Adjust testosterone, check sleep apnea, ensure hydration; use phlebotomy only when clinically necessary (Sleep apnea and erythrocytosis, 2012).
Mood changes: Avoid sharp injection peaks; consider the topical route or adjust the frequency; evaluate sleep and micronutrient status.
Abnormal uterine bleeding: Verify endometrial protection, evaluate dosing, consider ultrasound; rule out structural causes.
Acne/hirsutism: Dose-adjust and assess DHT; consider 5α-reductase modulation case-by-case and discuss fertility.
Clinical observation: The highest-risk side effects occur when therapy starts without adequate risk stratification or when dose escalation outruns monitoring. Most complications abate with dose correction, route change, and terrain optimization.

Integrating Lifestyle, Behavior, and Shared Decision-Making

Hormones amplify what lifestyle initiates. Without sleep consolidation, resistance training, cardiorespiratory fitness, and nutritional adequacy, hormone therapy underperforms.
Exercise:
Resistance training enhances bone mineral density and insulin sensitivity.
Aerobic work improves endothelial function.
Both attenuate aromatase via fat loss (Exercise and bone metabolism, 2020).
Nutrition:
Adequate protein, fiber, and phytonutrient diversity support the microbiome and detox pathways.
Alcohol moderation reduces estrogenic load and breast risk.
Stress regulation:
Elevated cortisol undermines sex steroid signaling; mind–body practices and sleep hygiene are essential.
I emphasize shared decision-making, present risks and benefits with data, and align plans with patient values. Education transforms adherence and safety.

Practical Algorithm: Putting It All Together

Evaluate baseline: history, goals, cancer/prostate/VTE risk, sleep, mood, cardiometabolic markers, body composition, GI function.
Correct terrain: sleep, nutrition, movement, microbiome support, micronutrient deficits.
Select modality: choose delivery route aligned with risk; start low and titrate based on symptoms and labs.
Support metabolism: use diet and targeted supplements; monitor estrogen metabolites when indicated.
Monitor and adjust: schedule labs and visits; use symptom scores; adjust dose/frequency/route to sustain physiologic targets.
Prevent and manage side effects: anticipate, educate, and intervene early; document shared decisions and outcomes.

EEstrogen’sCritical Window, WHI Misconceptions, and Modern Guidelines

The Women’s Health Initiative (WHI) used conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA), not bioidentical molecules. Early risk signals were concentrated in the progestin arm, yet headlines generalized these findings to all hormones (Manson et al., WHI outcomes, 2013). Subsequent analyses demonstrated nuance:
Estrogen-alone in hysterectomized women showed neutral to beneficial patterns for some endpoints, including breast cancer incidence and mortality (Chlebowski et al., 2020).
The critical window hypothesis supports starting therapy near menopause to optimize vascular and neuroprotective effects (Maki & Henderson, Critical window, 2016).
Modern guidance emphasizes individualization, rejects routine discontinuation at age 65, and supports continuation when risk–benefit is favorable (NAMS 2017 Position Statement, 2017; NAMS 2022 Update, 2022; ACOG Practice Bulletin, 2023).
My practice aligns with these updates by prioritizing bioidentical 17β-estradiol and micronized progesterone, favoring transdermal routes, and personalizing plans.

Estradiol, Cardiovascular and Brain Protection, and Discontinuation Risks

A body of evidence indicates that appropriately destradioladiol improves vascular and metabolic health, reduces events, and supports neuroprotection:
Endothelial benefits via NO synthase activation, reduced NF-κB, improved lipids, and plaque stability (Mendelsohn & Karas, Cardiovascular effects of estrogen, 2005).
Neuroprotection through PI3K/Akt, ERK, BBB integrity preservation, and microglial modulation (Liu et al., Estradiol neuroprotection, 2007; Arevalo et al., 2015).
Abrupt estrogen withdrawal increases cardiac and stroke risks due to autonomic destabilization, vascular tone shifts, and coagulation changes; tapering is safer (Grodstein et al., HT discontinuation CV implications, 2003).
In practice, I counsel patients on continuity and, when needed, careful tapering, while maintaining protective lifestyle interventions.

Testosterone–Estradiol Synergy and Avoiding Aromatase Inhibitors in Men

Estradiol and testosterone synergize to improve lipids, insulin, and visceral fat. Routine AI use can blunt these benefits:
Bisphenol A raises pain sensitivity, worsens metabolic parameters, and undermines bone health (Henry et al., AI musculoskeletal symptoms, 2018; Handelsman, Estrogen in men’s bone health, 2013).
Allowing physiological aromatization supports the integrity of the brain, bone, vascular, and metabolic systems.
I avoid routine AIs, monestradioladiol rather than preemptively blocking it, and use body composition strategies to modulate aromatization.

Sexual Health, Genitourinary Support, and MMen’sEstrogen Balance

Estrogen influences libido, arousal, vaginal mucosa, pelvic floor, and urogenital health. In men, balaestradiol supports libido, endothelium, and bone. I pair estradiol with local therapies (e.g., vagestradiol or DHEA) and pelvic rehab when indicated, while ensuring mmen’sE2/T ratios remain physiological.

My Clinical Observations: Translating Research into Outcomes

From my practice at Chiromed and collaborative care settings:
Women initiating transdermal 17β-estradiol near menopause report rapid improvements in cognition, sleep, and vasomotor symptoms; over 6–12 months, we see improvements in lipids, lower CRP, and better glycemic metrics with nutrition and resistance training.
Adding micronized progesterone stabilizes mood and sleep; patients report deeper, more restorative rest.
Thoughtful androgen support in women can enhance energy, bone, and sexual desire; monitoring hair/skin/lipids guides dosing.
Chronic pain patients often exhibit hormonal insufficiency; corticosteroids and progesterone reduce central sensitization; when combined with myofascial care, strength training, and anti-inflammatory nutrition, outcomes improve.
Deprescribing occurs naturally: fewer sedatives as sleep normalizes, reduced antidepressants with neurosteroid support, lower antihypertensives as endothelial function and autonomic tone improve.
Explore my clinical insights:
https://chiromed.com/
https://www.linkedin.com/in/dralexjimenez/

Practical Protocol Considerations and Rationale

I design protocols to match physiology, goals, and safety:
Comprehensive assessment:
Menstrual history, vasomotor symptoms, cognition, mood, sexual health, fracture risk, cardiometabolic markers, and family history.
Estradiol:
Initiate transdermal 17β-estradiol for brain, vascular, and bone signaling due to receptor congruence and lower thrombotic risk.
Progesterone:
Add oral micronized progesterone for uterine protection and neurocalm; avoid progestins due to their receptor promiscuity and immune effects.
Androgens:
Consider low-dose testosterone in women for bone, muscle, and libido with careful monitoring; in men, maintain physiologic dosing and avoid routine AIs.
Lifestyle medicine:
Progressive resistance training, zone-2 cardio, sleep optimization, stress management, and a phytonutrient-rich diet.
Gut–hormone axis:
Address dysbiosis, increase fiber and polyphenol intake, support liver detoxification, and normalize enterohepatic cycling.
Monitoring:
Track symptoms, vitals, lipids, CRP, glucose/insulin, DEXA, endometrial status, and cognitive screening as needed.
Each element is chosen to advance patient goals and respect biological signaling.

Myths and Misconceptions Corrected


““strogen causes breast cancer.””Evidence differentiates molecules: risks increased with progestin combinations started late in WHI; estrogen-alone data show neutral/beneficial patterns in specific groups. Bioidentestradiol with progesterone is distinct from CEE+MPA (Chlebowski et al., 2020; NAMS 2022 Update, 2022).
“”ll hormones are the same.””False. 17β-estradiol and micronized progesterone are physiologically coherent; synthetic analogs have different receptor promiscuity and effects (Stanczyk et al., 2013).
“top at 65.” Not evidence-based; discontinuation reverses gains. Continuation should be individualized (NAMS 2017 Position Statement, 2017; NAMS 2022 Update, 2022).
“Only treat hot flashes.””Estrogen is a longevity hormone that affects the brain, bones, heart, immune system, and sexual health.

Conclusion: Modern, Evidence-Based Hormone Optimization

Estrogen, specifically 17β-estradiol, paired with micronized progesterone, and testosterone where appropriate, supports neuroprotection, bone strength, cardiovascular resilience, immune modulation, and sexual vitality. Outcomes depend on molecule, route, dose, timing, and systemic context. By embracing modern evidence and systems biology, we can reduce polypharmacy, elevate quality of life, and practice true preventive medicine.

References

About Dr. Alexander Jimenez

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, provides integrative, functional, and evidence-based musculoskeletal and metabolic care. Clinical insights and educational resources are available at:
https://chiromed.com/
https://www.linkedin.com/in/dralexjimenez/

Keywords


hormone optimization, estrogen therapy, testosterone therapy, progesterone benefits, bioidentical hormones, transdeestradioladiol, micronized progesterone, androgen receptor, estrogen receptor, estrogen metabolites, COMT, methylation, estrobolome, microbiome, β-glucuronidase, bile acids, insulin sensitivity, bone density, cardiovascular risk, neurosteroids, sleep, erythrocytosis, prostate monitoring, VTE risk, functional medicine, clinical protocols, dosing strategies, side effect management, longevity, preventive medicine

Disclaimer


This educational content is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication or therapy without consulting your qualified healthcare provider.

SEO tags: hormone optimization, bioidentestradiol, micronized progesterone, transdermal estrogen safety, testosterone therapy men, aromatase inhibitors risks, menopause brain health, dementia prevention estrogen, cardiovascular endothelial function estrogen, bone density menopause therapy, estrobolome gut hormones, functional medicine hormone therapy, VTE risk transdermal estrogen, progesterone neurosteroid sleep, erythrocytosis testosterone management, Dr. Alexander Jimenez DC APRN FNP-BC, evidence-based endocrinology, WHI misconceptions and modern guidelines, NAMS hormone therapy position, androgen therapy women, deprescribing with hormone optimization

Proactive Healthcare: Putting Patients at the Center

Proactive Healthcare: Putting Patients at the Center

Proactive Healthcare: Putting Patients at the Center

Abstract

This educational post explores the critical need for a paradigm shift in modern medicine, moving from a reactive, symptom-based model to a proactive, patient-centered approach. I will explore the historical context of our current healthcare system, examining the influence of industry and standardized protocols that have led to a “pill for every ill” mentality. We will critically analyze the widespread use of medications like statins and their potential long-term consequences, particularly concerning cognitive health, supported by recent evidence. This discussion will highlight the physiological importance of cholesterol and the risks associated with its suppression. Furthermore, we will address the need for personalized, integrative medicine that accounts for an individual’s unique genetic makeup and lifestyle. I will present a case for prioritizing nutrition, hormone optimization, and root-cause analysis in clinical practice. The goal is to empower fellow practitioners to transcend the limitations of conventional sick care and embrace a proactive wellness model that restores vitality to our patients and reinvigorates our professional calling.

The Historical Shift Towards a Protocol-Driven Model

To understand where we are headed in healthcare, we must first look back at our journey. In the 1800s, medicine began to organize around structured protocols. By the early 1900s, the convergence of science and industry had fundamentally reshaped the landscape. Figures like John D. Rockefeller recognized the immense financial potential within the medical field. Now, let me be clear: I firmly believe that practitioners who do excellent work should be well-compensated. You are saving and improving lives, and your partnership in healing deserves reward.

However, we must also acknowledge the historical precedents where profit has taken precedence over well-being. Industries built around sugar, processed foods, and tobacco generated billions in revenue while contributing to widespread illness and death. When we see this pattern, we must question the systems that allow it.

A major shift occurred in the 1980s with the rise of Big Pharma. This era marked a fundamental shift in medical thinking, moving away from individualized care and toward standardized, protocol-driven treatments. A pivotal moment was in 1987, with the introduction of the first statin medication. This event solidified a new clinical mindset: run a blood test, identify a number that falls outside a “normal” range, and prescribe a pill to correct it. This reductionist approach has shaped the healthcare environment we navigate today.

The Statin Epidemic: Questioning the War on Cholesterol

Let’s examine the most prescribed medications in the United States to understand the scale of this issue. While drugs like metformin and ibuprofen are widely used, statins lead the pack. It’s estimated that by 2025, over 200 million patients will be on a statin. For decades, the prevailing dogma has been to suppress cholesterol levels at all costs. As a clinician, I’ve seen the real-world impact of this practice, and the evidence now compels us to question it.

What do we know about cholesterol? It is not an enemy to be eradicated. Physiologically, it is a foundational component of cellular health. Your brain, by volume, is predominantly built from cholesterol. It is essential for the formation of cell membranes, the synthesis of hormones (like estrogen, testosterone, and cortisol), and the production of vitamin D. When we aggressively lower cholesterol, especially in our aging and hospitalized patients, we are systemically depleting a critical building block.

  • Brain Health and Cholesterol: We are now facing an epidemic of Alzheimer’s disease and other forms of dementia, conditions once considered rare. A growing body of research suggests a correlation between low cholesterol levels and an increased risk of cognitive decline (Sparks et al., 2006). By shrinking the brain’s essential raw material, are we inadvertently contributing to this crisis?
  • Immune Function and Cholesterol: A fascinating study published in February 2025 revealed that cholesterol plays a vital role in fueling dendritic cells, which are key communicators in our immune system. These cells are activated by tumors and help orchestrate a robust immune response against cancer, particularly lung cancer (Ringel et al., 2023). Yet, the standard practice remains to “crush” cholesterol with statins. We must ask if this approach is undermining our body’s innate ability to defend itself.

The “here’s your number, here’s your pill” model is failing us. It treats a lab value as a number on a piece of paper, not the complex human being behind it.

The Systemic Challenge: Big Pharma, Insurance, and Government

The complexities of our healthcare system were amplified in 2010 with the endorsement of the Affordable Care Act. This brought Big Pharma, big insurance, and big government into the same room, all with a vested interest in the industry’s financial mechanics. The global pharmaceutical industry’s net profit in 2024 was an estimated 1.7 trillion dollars. This is pure profit, not top-line revenue. This immense financial success has been achieved within a system that spends trillions annually on “healthcare” while our population grows sicker.

This is the clinical reality I see in my practice and one you likely witness every day. Patients are not getting well. They are being managed, their symptoms bandaged, but the underlying drivers of disease remain unaddressed. This approach is not healing; it’s a cycle of symptom suppression that often leads to more prescriptions to manage the side effects of the first.

The Call for Personalized, Proactive Healthcare

A growing number of patients and practitioners are questioning this broken model. They are demanding something different, something more. The truth is, choice isn’t optional; it’s everything. Medicine has somehow forgotten this fundamental principle. A one-size-fits-all approach is illogical. We are all genetically and biochemically unique. How can we possibly expect the same dose of the same medication, following the same rigid protocol, to work for everyone? It defies common sense.

Today, we stand at a crossroads. We have a choice:

  • Continue as reactive sick-care professionals, waiting for disease to manifest before intervening.
  • Become proactive healthcare providers, empowering our patients to build and maintain wellness.

This requires a shift in mindset. We should aim for our patients to see us to stay well, not just because they are sick. It also requires humility. As a profession, what if admitting we were wrong about certain long-held beliefs is the most important thing we can do to get it right? It takes character to step back from dogma, look at the new evidence, and say, “There is a better way.”

Restoring Curiosity, Humanity, and Critical Thinking

To move forward, we must reintroduce three essential elements into our practice:

  1. Curiosity and Science: We must be lifelong learners, constantly evaluating new research. The principles of functional and integrative medicine are not based on conjecture but are backed by multiple studies. We must be willing to dig deeper and ask why a patient is experiencing symptoms. A person is not Prozac deficient; they are depressed for an underlying reason. Our job is to uncover that root cause.
  2. Humanity: We must remember that we are treating patients, not paper. How often do we find ourselves focused on lab results, reciting numbers, instead of looking our patient in the eye and engaging in a real conversation? The patient’s story, their lived experience, is as crucial as any lab value. We treat fathers, mothers, teachers, and grandparents—the very fabric of our society. Their well-being has a ripple effect on us all.
  3. Critical Thinking: We must challenge the status quo and not accept information without scrutiny. The COVID-19 pandemic, for many of us, was a stark reminder of how easily critical thinking can be suspended in favor of a singular, top-down narrative. When a Stanford virologist stated early on that a safe and effective vaccine would take a minimum of three to four years to develop based on all established scientific standards, it highlighted the unprecedented speed and subsequent controversy of what transpired. I encourage you to question everything, even the information presented here. Take the studies we provide, research them, and come to your own informed conclusions.

The Promise of Integrative and Nutritional Medicine

The good news is that the tide is turning. Major institutions are beginning to acknowledge the vital role of nutrition. A recent article from Johns Hopkins Medicine championed the idea that future doctors will advise on nutrition, fostering a more holistic and comprehensive approach to health (Johns Hopkins Medicine, 2024). This is something we in the functional medicine community have advocated for decades. As I’ve often said, your cells don’t know if they are Republican or Democrat; they only know if they are nourished or starved. Addressing nutrition is not an “alternative” therapy; it is a foundational pillar of health that significantly improves patient outcomes.

Similarly, the evidence supporting the protective roles of hormones is finally gaining traction. For years, we’ve taught that estrogen, when properly balanced and administered, does not cause cancer but, in fact, helps protect the heart, brain, and bones by preventing osteoporosis. The FDA’s willingness to reconsider its stance is a monumental step forward (U.S. Food & Drug Administration, 2023).

Overcoming Cognitive Inertia

One of the biggest obstacles to progress is cognitive inertia—the tendency to stick with default mental models and resist new information that challenges our existing beliefs. It’s confirmation bias in action. Statistically, about 20% of practitioners who attend advanced training and learn new, evidence-based protocols will never implement them. They will return to their comfort zone.

Albert Einstein famously said, “We cannot solve our problems with the same thinking we used when we created them.” We must consciously break free from this inertia. We must move from treating the masses to treating the individual. We must embrace personalized medicine while never losing sight of our shared humanity.

Your Role in the Future of Medicine

Today, March 27, 2026, marks a new beginning. Just as 1987 ushered in the era of the statin, today can be the day you commit to transforming your practice. History doesn’t remember the practitioners who simply followed the system; it remembers those who transformed it. That responsibility now belongs to you.

You have the choice to stay in your comfort zone or to make a change. This is about more than just a new treatment modality; it is about regaining the calling that brought you to medicine in the first place. It’s about seeing your patients return to you not with the same complaints, but with stories of transformation: “You saved my life. You saved my marriage.”

Let’s commit to a new path:

  • Let’s treat patients, not cases.
  • Let’s provide proactive healthcare, not reactive sick care.
  • Let’s be integrative, not just allopathic.
  • Let’s become wellness care providers.

This is our finest hour. Medicine is at a pivotal point, and we are the ones who will drive the change. By restoring freedom to our practice and our patients—freedom from outdated dogma, from censorship, and from a system that ignores our humanity—we can help our communities truly thrive.

References